We had expected glowing reports this Friday after the FDA review of the new HCV Gilead drug Sofosbuvir. What, then, to our utter surprise than to spot this promising FDA blurb today- three days prior to the upcoming FDA discourse. Whooo-doggies. By the way, the stock closed this afternoon at $69.01. Smokin’.
Nod’s suggestion. Ugggh! Buy stock. Nod take protein pill. Nod put helmet on and tighten safety belt. Nod like grape-flavored Sofosbuvir.